Kyle R. Leeman | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Kyle R. Leeman is active.

Explore More

Publication

Featured researches published by Kyle R. Leeman.

Tetrahedron Letters | 2003

On the photoisomerization of the benzisothiazole portion of ziprasidone

Thomas R. Sharp; Kyle R. Leeman; D.Eugene Bryant; George J. Horan

Abstract Photostability challenge of ziprasidone in solution shows that the benzisothiazole moiety undergoes isomerization to the corresponding benzthiazole. A model compound, 3-piperazinyl-1,2-benzisothiazole, also undergoes this photoisomerization. Identification of the products has been confirmed by synthesis of the proposed molecules.

Journal of Organic Chemistry | 2006

Aqueous Phosphoric Acid as a Mild Reagent for Deprotection of tert-Butyl Carbamates, Esters, and Ethers

Bryan Li; Martin A. Berliner; Richard A. Buzon; Charles K.-F. Chiu; Stephen T. Colgan; Takushi Kaneko; Nandell F. Keene; William Kissel; Tung Le; Kyle R. Leeman; Brian Marquez; Ronald Morris; Lisa Newell; Silke Wunderwald; Michael Witt; John Weaver; and Zhijun Zhang; Zhongli Zhang

Organic Letters | 2011

Mild decarboxylative activation of malonic acid derivatives by 1,1'-carbonyldiimidazole.

Danny Lafrance; Paul Bowles; Kyle R. Leeman; Robert J. Rafka

Archive | 2003

Controlled synthesis of ziprasidone and compositions thereof

Frank Robert Busch; Adam Worth Grobin; Harry Ralph Howard; Kyle R. Leeman

Tetrahedron Letters | 2003

Aqueous phosphoric acid as a mild reagent for deprotection of the t-butoxycarbonyl group

Bryan Li; Raymond J. Bemish; Richard A. Buzon; Charles K.-F. Chiu; Stephen T. Colgan; William Kissel; Tung Le; Kyle R. Leeman; Lisa Newell; Joshua Roth

Archive | 2003

Ziprasidone composition and synthetic controls

Frank Robert Busch; Adam Worth Grobin; Kyle R. Leeman; Harry Ralph Howard

Organic Process Research & Development | 2016

Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling

Shengquan Duan; David William Place; Hahdi H. Perfect; Nathan D. Ide; Mark T. Maloney; Karen Sutherland; Kristin E. Price Wiglesworth; Ke Wang; Mark Olivier; Fangming Kong; Kyle R. Leeman; Jon Blunt; John Draper; Marie McAuliffe; Maria M. O’Sullivan; Denis Lynch

Organic Process Research & Development | 2016

Palbociclib Commercial Manufacturing Process Development. Part II: Regioselective Heck Coupling with Polymorph Control for Processability

Mark T. Maloney; Brian P. Jones; Mark Olivier; Javier Magano; Ke Wang; Nathan D. Ide; Andrew S. Palm; David R. Bill; Kyle R. Leeman; Karen Sutherland; John Draper; Adrian M. Daly; Joseph Keane; Denis Lynch; Marie O’Brien; Joanne Tuohy

Organic Process Research & Development | 2014

Synthesis of Filibuvir. Part I. Diastereoselective Preparation of a β-Hydroxy Alkynyl Oxazolidinone and Conversion to a 6,6-Disubstituted 2H-Pyranone

Robert A. Singer; John A. Ragan; Paul Bowles; Esmort Chisowa; Brian G. Conway; Eric M. Cordi; Kyle R. Leeman; Leo J. Letendre; Janice E. Sieser; Gregory W. Sluggett; Corey L. Stanchina; Holly Strohmeyer; Jon Blunt; Stuart Taylor; Ciaran Byrne; Denis Lynch; Sandra Mullane; Maria M. O’Sullivan; Marcella Whelan

Organic Process Research & Development | 2016

Palbociclib Commercial Manufacturing Process Development. Part III. Deprotection Followed by Crystallization for API Particle Property Control

Brian P. Chekal; Jason Ewers; Steven M. Guinness; Nathan D. Ide; Kyle R. Leeman; Ronald J. Post; Anil M. Rane; Karen Sutherland; Ke Wang; Mark Webster; Gregory J. Withbroe; John Draper; Denis Lynch; Marie McAuliffe; Joseph Keane

Explore More